Building a More Connected DSMB: Better Integrating Ethics Review and Safety Monitoring

REFERENCES

• Anderson, E. E. (2006). A qualitative study of non-Affiliated, non-scientist Institutional Review Board members. Accountability in Research, 13(2):135–155.
   PubMedGoogle Scholar
• Buchanan, D. and Miller, F. G. (2005). Principles of early stopping of randomized trials for efficacy: A critique of equipoise and an alternative nonexploitation ethical framework. Kennedy Institute of Ethics Journal, 15(2):161–178.
   PubMed Web of Science ®Google Scholar
• Califf, R. M., Morse, M. A., Wittes, J., Goodman, S. N., Nelson, D. K., DeMets, D. L, Iafrate, R. P., and Sugarman, J. (2003). Toward protecting the safety of participants in clinical trials. Controlled Clinical Trials, 24(3):256–271.
   PubMedGoogle Scholar
• DeMets, D. L. and Friedman, L. M. (2006). The data monitoring experience in the cardiac arrhythmia trial: The need to be prepared early. In: Data Monitoring in Clinical Trials: A Case Studies Approach. DeMets, D. L., Furberg, C. D., and Friedman, L. M. ( eds.). New York: Springer; pp. 198–208.
   Google Scholar
• DeMets, D. L., Fost, N., and Powers, M. (2006). An Institutional Review Board dilemma: Responsible for safety monitoring but not in control. Clinical Trials, 3(2):142–148.
   PubMed Web of Science ®Google Scholar
• DeMets, D. L., Furberg, C. D., and Friedman, L. M. (2006). Data Monitoring in Clinical Trials: A Case Studies Approach. New York: Springer.
   Google Scholar
• Department of Health and Human Services. (1996). Waiver of Informed Consent Requirements in Certain Emergency Research. Federal Register.
   Google Scholar
• Department of Health and Human Services Office of Inspector General. (2013). Data and Safety Monitoring Boards in NIH Clinical Trials: Meeting Guidance, But Facing Some Issues. OEI-12-11-00070. Available at https://oig.hhs.gov/oei/reports/oei-12-11-00070.pdf. Last accessed August 9, 2013.
   Google Scholar
• Dixon, D. O., Weiss, S., Cahill, K., Fox, L., Love, J., McNamara, J., and Soto-Torres, L. (2011). Data and safety monitoring policy for National Institute of Allergy and Infectious Diseases clinical trials. Clinical Trials, 8(6):727–735.
   PubMed Web of Science ®Google Scholar
• Droppert, P. (2012). J&J Prostate Cancer Trial Shouldn’t Have Been Stopped Early. Xconomy. Available at http://www.xconomy.com/national/2012/06/03/jj-prostate-cancer-trial-shouldnt-have-been-stopped-early/. Last accessed September 26, 2013.
   Google Scholar
• Duncan, W., Smith, A. N., Freedman, L. S., Alderson, M. R., Arnott, S. J., Bleehen, N. M., Bond, W. H. Crowther, D., Deeley, T. J., Duthie, H. L., Dykes, P. W., Fielding, L. P., Flatman, G. E., Goligher, J. C., Hawley, P. R., Hughes, L. E., Jolin, C. a. F., Koriech, O. M., Morson, B. C., Oates, G. D., Peckham, M. J., Sandland, M. R., Schofield, P. F., Slack, W., Slaney, G., Smith, J. a. R., Scott, J., Whitehouse, J. M. A., Wrigley, P. F. M., and York-Maso, A. (1984). The evaluation of low dose pre-operative X-ray therapy in the management of operable rectal cancer: Results of a randomly controlled trial. British Journal of Surgery, 71(1):21–25.
   PubMedGoogle Scholar
• Ellenberg, S. and Siegel, J. P. (2006). FDA and clinical trial data monitoring committees. In: Data Monitoring in Clinical Trials: A Case Studies Approach. DeMets, D. L., Furberg, C. D., and Friedman, L. M. ( eds.). New York: Springer.
   Google Scholar
• Ellenberg, S. S., Fleming, T. R., and DeMets, D. L. (2002). Data Monitoring Committees in Clinical Trials: A Practical Perspective. Statistics in Practice. Chichester, West Sussex; Hoboken, N.J.: J. Wiley.
   Google Scholar
• Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., and Wolmark, N. (1998). Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute, 90(18):1371–1388.
   Google Scholar
• Fleming, T. R., Ellenberg, S., and DeMets, D. (2002). Monitoring clinical trials: Issues and controversies regarding confidentiality. Statistics in Medicine, 21(19):2843–2851.
   PubMed Web of Science ®Google Scholar
• Fleming, T. R., Sharples, K., McCall, J., Moore, A., Rodgers, A., and Stewart, R. (2008). Maintaining confidentiality of interim data to enhance trial integrity and credibility. Clinical Trials, 5(2):157–167.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. (2006). Guidance for Clinical Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees. Available at http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM127073.pdf. Last accessed August 13, 2013.
   Google Scholar
• Freedman, B. (1987). Equipoise and the ethics of clinical research. New England Journal of Medicine, 317(3):141–145.
   PubMed Web of Science ®Google Scholar
• Gordon, V. M., Sugarman, J., and Kass, N. (1998). Toward a more comprehensive approach to protecting human subjects: The interface of data safety monitoring boards and Institutional Review Boards in randomized clinical trials. IRB: Ethics and Human Research 20(1):1.
   PubMedGoogle Scholar
• Grant, A. M., Altman, W. H., Babiker, A. B., Campbell, M. K., Clemens, F. J., Darbyshire, J. H., Elbourne, D. R., McLeer, S. K., Parmar, M. K. B., Pocock, S. J., Spiegelhalter, D. J., Sydes, M. R., Walker, A. E., and Wallace, S. A. (2005). Issues in data monitoring and interim analysis of trials. Health Technology Assessment (Winchester, England), 9(7):1–238.
   Web of Science ®Google Scholar
• Greenberg, B. G. (1988). Organization, review, and administration of cooperative studies (Greenberg Report): A report from the Heart Special Project Committee to the National Advisory Heart Council, May 1967. Controlled Clinical Trials, 9(2):137–148.
   PubMedGoogle Scholar
• Herson, J. (2009). Data and Safety Monitoring Committees in Clinical Trials. Chapman & Hall/CRC Biostatistics Series 30. Boca Raton, FL: Chapman & Hall/CRC.
   Google Scholar
• Hulley, S. B., Grady, D., Vittinghoff, E., and Williams, O. D. (2006). Consideration of Early Stopping and Other Challenges in Monitoring the Heart and Estrogen/Progestin Replacement Study. In Data Monitoring in Clinical Trials: A Case Studies Approach. DeMets, D. L., Furberg, C. D., and Friedman, L. M. ( eds.). New York: Springer; pp. 236–247.
   Google Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. (1996). Guideline for Good Clinical Practice E6 (R1). Available at http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf. Last accessed April 20, 2013.
   Google Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. (1998). Guideline for Good Clinical Practice: Statistical Principles for Clinical Trials (E9). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf. Last accessed August 13, 2013.
   Google Scholar
• Korn, E. L. and Freidlin, B. (2011). Inefficacy interim monitoring procedures in randomized clinical trials: The need to report. The American Journal of Bioethics, 11(3):2–10.
   PubMed Web of Science ®Google Scholar
• Lilford, R. J., Braunholtz, D., Edwards, S., and Stevens, A. (2001). Monitoring clinical trials—Interim data should be publicly available. BMJ, 323(7310):441–442.
   PubMed Web of Science ®Google Scholar
• Malmqvist, E., Juth, N., Lynöe, N., and Helgesson, G. (2011). Early stopping of clinical trials: Charting the ethical terrain. Kennedy Institute of Ethics Journal, 21(1):51–78.
   PubMed Web of Science ®Google Scholar
• Miller, A. B., Buring, J., and Williams, O. D. (2006). Stopping the carotene and retinole efficacy trial: The viewpoint of the Safety and Endpoint Monitoring Committee. In: Data Monitoring in Clinical Trials: A Case Studies Approach. DeMets, D. L., Furberg, C. D., and Friedman, L. M. ( eds.). New York: Springer; pp. 220–227.
   Google Scholar
• Moher, D., Hopewell, S., Schulz, K. F, Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., and Altman, D. G. (2010). CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials. BMJ, 340 (March23):c869–c869.
   PubMed Web of Science ®Google Scholar
• Morse, M. A. and Califf, R. M. (2001). Monitoring and ensuring safety during clinical research. JAMA, 285(9):1201–1205.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. (1998). NIH Policy for Data and Safety Monitoring. Available at http://grants.nih.gov/grants/guide/notice-files/not98-084.html. Last accessed April 25, 2013.
   Google Scholar
• Office of the Inspector General. (1998). Institutional Review Boards: A Time for Reform. Available at http://oig.hhs.gov/oei/reports/oei-01-97-00193.pdf. Last accessed May 3, 2013.
   Google Scholar
• Pocock, S., Wilhelmsen, L., Dickstein, K., Francis, G., and Wittes, J. (2004). The data monitoring experience in the MOXCON trial. European Heart Journal, 25(22):1974–1978.
   PubMed Web of Science ®Google Scholar
• Pogue, J. and Yusuf, S. (2006). Data monitoring in the randomized evaluation of strategies for left ventricular dysfunction pilot study: When reasonable people disagree. In: Data Monitoring in Clinical Trials: A Case Studies Approach. DeMets, D. L., Furberg, C. D., and Friedman, L. M. ( eds.). New York: Springer; pp. 330–336.
   Google Scholar
• Redmond, C. K., Constantino, J. P., and Colton, T. (2006). Challenges in monitoring the breast cancer prevention trial. In Data Monitoring in Clinical Trials: A Case Studies Approach. DeMets, D. L., Furberg, C. D., and Friedman, L. M. ( eds.). New York: Springer; 118–135.
   Google Scholar
• Rider, W. D., Palmer, A., Mahoney, L. J., and Robertson, C.T. (1977). Preoperative irradiation in operable cancer of the rectum: Report of the Toronto trial. Canadian Journal of Surgery, 20(4):335–338.
   Google Scholar
• Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., Carles, J., Mulders, P. F. A, Basch, E., Small, E., Saad, F., Schrijvers, D., Van Poppel, H., Gerritsen, W. R., Flaig, T. W., George, D. J., Yu, E. Y., Efstathiou, E., Pantuck, A., Winquist, E., Higano, C., Taplin, M., Park, Y., Kheoh, T., Griffin, T., Scher, H. L., and Rathkopf, D. E. (2013). Abiraterone in metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine, 368(2):138–148.
   PubMed Web of Science ®Google Scholar
• Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C., de Souza, P., Fizazi, K., Mainwaring, P. N., Rodriguez, J. M., Ng, S., Carles, J., Mulders, P., Kheoh, T., Griffin, T. W., Small, E. J., Scher, H. I., and Rathkopf, D. E. (2012). Interim Analysis (IA) results of COU-AA-302, a randomized, Phase III Study of Abiraterone Acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). In: Clinical Science Symposium, New Paradigms for Hormone Therapy in Prostate Cancer. Chicago. Available at http://meetinglibrary.asco.org/content/95300-114. Last accessed September 29, 2013.
   Google Scholar
• Sengupta, S. and Lo, B. (2003). The roles and experiences of nonaffiliated and non-scientist members of Institutional Review Boards. Academic Medicine: Journal of the Association of American Medical Colleges, 78(2):212–218.
   PubMed Web of Science ®Google Scholar
• Shah, S. K., Dawson, L., Dixon, D. O., and Lie, R. K. (2011). Should sponsors and DSMBs share interim results across trials? Journal of Acquired Immune Deficiency Syndromes, 58(5):433–435.
   PubMed Web of Science ®Google Scholar
• Slutsky, A. S. and Lavery, J. V. (2004). Data safety and monitoring boards. The New England Journal of Medicine, 350(11):1143–1147.
   PubMed Web of Science ®Google Scholar
• Sydes, M. R., Altman, D. G., Babikera, A. B., Parmar, M. K., and Spiegelhalter, D. J. (2004). Reported use of data monitoring committees in the main published reports of randomized controlled trials: A cross-sectional study. Clinical Trials, 1(1):48–59.
   PubMedGoogle Scholar
• Taylor, H. A., Chaisson, L., and Sugarman, J. (2008). Enhancing communication among data monitoring committees and Institutional Review Boards. Clinical Trials, 5(3):277–282.
   PubMed Web of Science ®Google Scholar
• Tereskerz, P. M., Guterbock, T. M., Kermer, D. A., and Moreno, J. D. (2011). An opinion and practice survey on the structure and management of data and safety monitoring boards. Accountability in Research, 18(1):1–30.
   PubMed Web of Science ®Google Scholar
• Thomas, D. E. and Snappin, S. (2002). Guidelines for Data and Safety Monitoring Boards. Merck. Available at: http://dida.library.ucsf.edu/lawsuits.jsp. Last accessed July 1, 2014.
   Google Scholar
• Wheatley, K. and Clayton, D. (2003). Be skeptical about unexpected large apparent treatment effects: The case of an MRC AML12 randomization. Controlled Clinical Trials, 24(1):66–70.
   PubMedGoogle Scholar
• Wittes, J. (1993). Behind closed doors: The data monitoring board in randomized clinical trials. Statistics in Medicine, 12(5–6):419–424.
   PubMed Web of Science ®Google Scholar
• World Medical Association. (2013). World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA, 310(20):2191–2194.
   Google Scholar